Gilead Sciences, Inc. Website

Gilead Sciences, Inc.

NasdaqGS-GILD

Basic

  • Market Cap

    $81.06B

  • EV

    $100.64B

  • Shares Out

    1,245.85M

  • Revenue

    $27.45B

  • Employees

    18,000

Margins

  • Gross

    77.52%

  • EBITDA

    46.14%

  • Operating

    36.15%

  • Pre-Tax

    3.92%

  • Net

    1.77%

  • FCF

    28.78%

Returns (5Yr Avg)

  • ROA

    6.2%

  • ROTA

    -26.44%

  • ROE

    19.05%

  • ROCE

    19.91%

  • ROIC

    16.09%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $82.7

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $5,524M

  • Net Debt

    $19.67B

  • Debt/Equity

    1.44

  • EBIT/Interest

    10.25

Growth (CAGR)

  • Rev 3Yr

    2.4%

  • Rev 5Yr

    4.22%

  • Rev 10Yr

    7.22%

  • Dil EPS 3Yr

    17.45%

  • Dil EPS 5Yr

    -38.82%

  • Dil EPS 10Yr

    -17.63%

  • Rev Fwd 2Yr

    1.58%

  • EBITDA Fwd 2Yr

    2.6%

  • EPS Fwd 2Yr

    3.4%

  • EPS LT Growth Est

    8.23%

Dividends

  • Yield

  • Payout

    776.95%

  • DPS

    $3.02

  • DPS Growth 3Yr

    3.17%

  • DPS Growth 5Yr

    5.23%

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

    4.68%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Total Revenues

22,449

24,689

27,305

27,281

27,116

27,450

Total Revenues % Chg.

1.5%

10%

10.6%

-0.1%

-0.6%

1.5%

Cost of Goods Sold, Total

4,675

3,691

5,526

5,657

6,019

6,170

Gross Profit

17,774

20,998

21,779

21,624

21,097

21,280

Selling General & Admin Expenses, Total

4,381

5,112

5,246

5,673

5,537

5,580

R&D Expenses

4,055

4,927

4,601

4,998

5,758

5,778

Other Operating Expenses, Total

8,436

10,039

9,847

10,671

11,295

11,358

Operating Income

9,338

10,959

11,932

10,953

9,802

9,922

Interest Expense, Total

-995

-984

-1,001

-935

-944

-968

Interest And Investment Income

376

376

406

Net Interest Expenses

-995

-984

-1,001

-559

-568

-562

Currency Exchange Gains (Loss)

22

-23

-21

-21

-21

Other Non Operating Income (Expenses)

605

244

-6

-279

11

4

EBT, Excl. Unusual Items

8,970

10,219

10,902

10,094

9,224

9,343

Restructuring Charges

-527

-590

Merger & Related Restructuring Charges

-920

Gain (Loss) On Sale Of Investments

1,241

-1,662

-610

-657

-167

75

Asset Writedown

In Process R&D Expenses

-5,051

-5,968

-939

-3,644

-1,205

-7,285

Legal Settlements

-1,075

-525

-525

Other Unusual Items

21

60

57

EBT, Incl. Unusual Items

5,160

1,669

8,278

5,814

6,860

1,075

Income Tax Expense

-204

1,580

2,077

1,248

1,247

616

Earnings From Continuing Operations

5,364

89

6,201

4,566

5,613

459

Minority Interest

22

34

24

26

52

26

Net Income

5,386

123

6,225

4,592

5,665

485

Net Income to Common Incl Extra Items

5,386

123

6,225

4,592

5,665

485

Net Income to Common Excl. Extra Items

5,386

123

6,225

4,592

5,665

485

Total Shares Outstanding

1,266

1,254

1,254

1,247

1,246

1,246

Weighted Avg. Shares Outstanding

1,270

1,257

1,256

1,255

1,248

1,247.8

Weighted Avg. Shares Outstanding Dil

1,277

1,263

1,262

1,262

1,258

1,254.5

EPS

4.2

0.1

5

3.7

4.5

0.4

EPS Diluted

4.2

0.1

4.9

3.6

4.5

0.4

EBITDA

10,742

12,439

13,982

13,056

12,495

12,665

Effective Tax Rate

-4%

94.7%

25.1%

21.5%

18.2%

57.3%